Product Usage: This product is intended for research purposes only.
All product information available on this website is for educational purposes only. Any form of bodily introduction into humans or animals is strictly prohibited by law. This product should only be handled by licensed and qualified professionals. It is not a drug, food, or cosmetic, and must not be misbranded, misused, or mislabeled as such.
Livagen, 20mg
During our packaging transition, you may receive products with either our previous or updated label. Rest assured, the formulation, purity and quality remain exactly same as standards.
Livagen is a synthetic bioregulatory peptide being studied for its role in regulating DNA structure and gene expression. Research interest centers on its proposed capacity to promote chromatin decondensation, with effects most extensively studied in lymphocyte models alongside investigations into immune system modulation across cardiac, gastrointestinal, and neural tissue models. Research applications include chromatin structure research, immune signalling pathway studies, and nociceptive pathway investigation.
- High Purity – 99% Purity Guaranteed
- Independently Lab Tested
- Research Grade Quality
- For Laboratory Research Use Only
3D Molecular Structure
Drag to rotate · scroll to zoom| Chemical Formula | C18H31N5O9 |
|---|---|
| Synonyms | SCHEMBL5967826 |
| Molar Mass | 461.5 g/mol |
| CAS Number | 195875-84-4 |
| PubChem CID | 87919683 |
| Total Compound Content | 20mg per vial |
| Shelf Life | 36 months |
Every batch is independently lab tested for identity, purity and potency. View our lab testing program →
What methods are used to study Livagen's proposed effect on chromatin decondensation in lymphocyte models?
Chromatin accessibility assays (such as ATAC-seq or micrococcal nuclease digestion-based methods) and microscopy-based heterochromatin/euchromatin ratio quantification are standard approaches for studying Livagen's reported effects on chromatin structure in lymphocyte cell models. These methods allow researchers to compare chromatin organisation state before and after compound exposure, often paired with downstream gene expression analysis (RNA-seq or targeted qPCR) to connect any observed chromatin structural change to functional transcriptional outcomes.
How is Livagen's immune modulation studied across different tissue model systems?
Tissue-specific immune signalling research with Livagen typically uses isolated immune cell populations relevant to each tissue context — cardiac-resident immune cells, gut-associated lymphoid tissue cells, and neural-immune interface cell populations (such as microglia) — measuring cytokine profiles and immune cell activation markers following compound exposure in each tissue-specific model. Comparative analysis across these tissue contexts allows researchers to determine whether Livagen's immune-modulatory mechanism is tissue-general or exhibits tissue-specific variation.
What experimental approaches investigate Livagen's reported influence on nociceptive signaling pathways?
Rodent behavioral nociception models (such as von Frey filament mechanical sensitivity testing or thermal withdrawal latency assays) combined with molecular analysis of pain-signalling pathway components (such as TRPV1 channel expression or neuroinflammatory markers in dorsal root ganglia) are used to study Livagen's relevance to nociceptive pathway research. These combined behavioral and molecular endpoints allow researchers to connect any functional change in pain-related behavior to underlying signalling pathway modulation.
